Navigation Links
Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men

Prognostic factors commonly used by clinicians to assess men with prostate cancer do not adequately predict survival outcomes in Asian men living in America, according to the first comprehensive ethnic analysis of Asian-American men with prostate cancer. Published in the September 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study showed that compared to white men, most Asian ethnic groups except South Asians paradoxically have better outcomes despite having worse prognostic profiles at the time of diagnosis. The study is the first to report prostate cancer survival data for Korean, South Asian and Vietnamese men living in the U.S.

In the U.S. in 2007, over 218,000 men are expected to be diagnosed with prostate cancer and over 27,000 will die. Established prognostic factors include age, summary stage, primary treatment, histologic grade, socioeconomic status, and year of diagnosis. Epidemiologic studies have identified racial differences in incidence and mortality, with African-American men being at greater risk than other races. Asian-American men as a single, ethnic group have the lowest incidence of disease and the lowest mortality rate. The reasons for these racial differences remain poorly studied.

In particular, the risk among different Asian ethnicities is poorly understood, in part, because most studies have aggregated all Asians into a single racial category, ignoring the diverse ethnicities that make up Asia. The few that have tried to analyze by Asian ethnicity have typically analyzed only a few ethnicities, missing significant Asian-American ethnic populations in the process. Interestingly, the data to date show that compared to non-Hispanic white Americans, some Asian ethnicities, such as Japanese-Americans, have higher survival rates, despite worse clinical disease, whereas others, such as Filipino-Americans, have worse survival rates. However, South Asians e.g., Indians, Pakistanis Bangladesh, etc. who represent the third largest Asian subgroup in America, have never been studied for prostate cancer.

Dr. Anthony Robbins of the California Cancer Registry in Sacramento, and co-investigators compared prognostic factors and survival rates of 116,916 men (108,076 whites and 8,840 Asians from the six largest represented Asian ethnicities - Chinese, Filipino, Japanese, Korean, South Asian, and Vietnamese) diagnosed with prostate cancer.

Dr. Robbins and his coauthors found that for each Asian ethnic subgroup, prognostic risk profiles were worse compared to whites. For example, all Asian ethnicities were more likely to have more advanced disease and use non-curative therapies. However, for all Asian ethnicities except South Asians, survival rates were equal to or better than whites. Japanese-Americans, for example, had significantly lower hazard ratio compared to non-Hispanic white Americans (34% lower). In contrast, South Asian-Americans had significantly higher hazard ratio compared to non-Hispanic white Americans (40% higher).

The study should help physicians more accurately apply prognostic factors to their prostate cancer patients. The authors conclude, these results argue that traditional prognostic factors for survival from prostate cancer (stage, grade, treatment, age, year of diagnosis, and socioeconomic status), do not explain why most Asian men have better survival compared to whites, but they do explain the poorer survival of South Asian men compared to whites.


Contact: Amy Molnar
John Wiley & Sons, Inc.

Related medicine news :

1. Conventional pap smears techniques to detect cervical cancer are here to stay
2. Are Conventional Tests for Heart attacks Reliable?
3. Paramedics save more lives following unconventional rules
4. Coronal Multiplanar Reformatted Images to Replace the Conventional Ones
5. Nitiol Stents A Better Alternative for the Conventional Stents
6. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
7. Alternative to the Conventional Seizure Treatment
8. No Health Benefits from Organic Milk Compared to Conventional Milk
9. Unconventional Hospital Costs For Children Affected By Flu
10. Study Challenges Conventional Treatment of Traumatic Brain Injury
11. Dental x-rays to prognosticate heart attacks
Post Your Comments:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: